Document is current

Article History

Received: 21 September 2025

Accepted: 14 January 2026

First Online: 9 February 2026

Declarations

:

: All the authors declare no conflict of interest in relation to this manuscript. Outside this scope, Dr Rao, and Ioannidis worked as a consultant and speaker for Allergan Aesthetics, an AbbVie company (Irvine, CA); Dr Michon is a consultant and speaker for Allergan Aesthetics, an AbbVie Company, consultant for Galderma Canada and SkinCeuticals Canada, L’Oréal Paris; Karim Sayed is a consultant to, speaker for, and has received honoraria from L’oréal/Skinceuticals, Teoxane, Lutronic, Cynosure and Allergan, an AbbVie Company (Irvine, CA); Dr Philipp-Dormston reports being a clinical trial investigator, scientific advisor, and/or speaker for Allergan Aesthetics, an Abbvie company (Irvine, CA), Galderma (Lausanne, Switzerland), Merz Pharmaceuticals GmbH and Evolus. He is also Senior President of the German Society for Botulinum and Filler Treatment (DGBT); Dr Carruthers has been a consultant and researcher for Alastin, Appiell, Allergan Aesthetics, an AbbVie Company, Avari, Bonti (now with Allergan/AbbVie), Evolus, Fount Bio, In Mode, Jeune Aesthetics, Merz, and Revance Biopharma. She is an author and editor for Elsevier and “Up to Date” Neuromodulators and Fillers, as well as an assistant editor for Dermatologic Surgery; Dr Wu is a speaker and consultant for Allergan Aesthetics, an Abbvie Company, Merz Pharmaceuticals GmbH; Dr Webb is cofounder of the AesthetiSIM TM . Dr Rahman has nothing to disclose. 

: This article does not contain any studies with human participants or animals performed by any of the authors.

: For this type of study informed consent is not required.